Morning infusions may boost lung cancer treatment
NCT ID NCT06882174
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at whether giving pembrolizumab infusions in the morning improves outcomes for people with metastatic non-small cell lung cancer. 58 participants will be randomly assigned to morning or standard scheduling. The goal is to see if timing affects how long the cancer stays under control and if this approach is practical for a larger trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab
- What this could lead to
- If timing matters, this could improve survival without extra cost or side effects, and lead to a larger study.
- What could go wrong
- This is a small pilot study, not yet recruiting. The benefit of timing is unproven, and results may not change standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
- Can a new drug shrink Hard-to-Treat tumors?
- Breath test may reveal who benefits from lung cancer immunotherapy
- Targeted radiation and immunotherapy join forces against Hard-to-Treat lung cancer
- Triple-Drug cocktail targets tough lung cancer mutations